INDEX // 06
Frequently asked questions about the blend
Twenty-five questions on BPC-157 TB-500 — definition, mechanism, evidence, dosing, safety, and access — each answered directly and cited to a study where the answer is quantitative.
Evidence and the data gap
The state of the evidence on the BPC-157 TB-500 blend, in three questions: what the latest research shows, what reviewers conclude, and whether the combination has been trialed in humans.
Definition and naming
What the BPC-157 TB-500 blend is, what it contains, and how the two peptides differ.
What it is studied for
Each repair claim traces to single-compound, mostly animal data — never a combination trial.
Mechanism and synergy
How each peptide works, and what the synergy claim does and does not rest on.
Dosing, half-life, and reconstitution
Research-context dosing facts only — no human guidance, no validated blend protocol.
Side effects and safety considerations
On side effects and safety considerations: human safety data are limited to the individual constituents, and one signal warrants explicit framing.
Regulatory and legal status
Approval, anti-doping, and FDA 503A status — answered from the audited record. Full detail is on Wolverine legal status and FDA 503A category.